Abbott Touts Compliance Program In Letter To Sen. Grassley
Executive Summary
Abbott believes its ethics and compliance program is "admirable," the company told Senate Finance Committee Chairman Charles Grassley (R-Iowa)
You may also be interested in...
Abbott Avoids Compliance Requirements In Kos Off-Label Marketing Settlement
A $41 million settlement of kickback and off-label marketing allegations involving Kos Pharmaceuticals’ cholesterol drugs will not result in new compliance requirements for parent company, Abbott Laboratories.
Abbott Avoids Compliance Requirements In Kos Off-Label Marketing Settlement
A $41 million settlement of kickback and off-label marketing allegations involving Kos Pharmaceuticals’ cholesterol drugs will not result in new compliance requirements for parent company, Abbott Laboratories.
Vioxx Hearing May Be Sign Of Things To Come Under Medicare Rx
The Senate Finance Committee should continue to review FDA's drug safety procedures in light of the upcoming expansion of the Medicare program, Ranking Democrat Max Baucus (D-Mont.) maintained during the committee's Nov. 18 hearing on Vioxx